News

Kairos Pharma Outlines 2025 Plans and Exciting Developments

Kairos Pharma Outlines 2025 Plans and Exciting Developments

Exciting Developments from Kairos Pharma

Kairos Pharma Ltd. (NYSE American: KAPA), a pioneering clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies aimed at overcoming cancer drug resistance and immune suppression. In a recent communication to stakeholders, the management team provided an insightful update on the company's journey, outlining key accomplishments from 2024 and laying out a strategic outlook for 2025.

Key Accomplishments of 2024

Throughout 2024, Kairos Pharma focused on building a robust foundation grounded in breakthrough science. This strategy enabled the company to bridge the gap between cutting-edge research and practical, impactful therapeutics. Notable achievements include:

  • Successful completion of the Initial Public Offering, marking a significant listing of common stock on the NYSE American.
  • Collaboration with PreCheck Health Services to enhance a biomarker panel for identifying patients likely to respond to ENV105.
  • Collaborative efforts with the City of Hope Cancer Center as part of the Phase 2 clinical trial of ENV 105 for treating prostate cancer.
  • Administering the first dose to a patient in the combination therapy trial of ENV105 and Osimertinib for EGFR-driven lung cancer.
  • Active participation and presentations at numerous investor conferences to build awareness within the investment community.
  • Initiating research coverage through renowned healthcare analysts in the industry.
  • Securing $3.5 million in gross proceeds from a PIPE transaction to fuel ongoing clinical trials and enhance preclinical asset development.
  • Strengthening patent protections across domestic and international markets to safeguard valuable technologies.

Strategic Vision for 2025

Looking ahead to 2025, Kairos Pharma is excited about upcoming milestones that are poised to significantly advance its mission. The planned initiatives include:

  • Continuing the execution of the Phase 2 randomized clinical trial of ENV 105 for prostate cancer.
  • Advancing the Phase 1 trial focusing on non-small cell lung cancer.
  • Providing updates on safety and interim efficacy data, with initial insights expected in the first half of 2025 for prostate cancer.
  • Presenting pivotal data at national scientific events that will showcase advancements in research.
  • Conducting Pre-IND studies for KROS 101, with findings anticipated for publication.
  • Beginning discussions for potential partnerships to further drive research initiatives.

Commitment to Patients and Research

Kairos Pharma remains dedicated to its mission of transforming the landscape of cancer treatment. The company believes in the significant potential of its therapies, which are based on innovative scientific principles, to create lasting change in the treatment of neoplastic disorders. With a strong focus on the needs of patients and the commitment of its partners and shareholders, Kairos Pharma aims to expand its scientific endeavors while maximizing shareholder value both now and in the future.

About Kairos Pharma Ltd.

Headquartered in Los Angeles, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics. The company leverages advancements in structural biology to tackle drug resistance and immune suppression encountered in cancer treatments. Its lead therapy, ENV105, specifically targets CD105, a protein linked to resistance against existing cancer therapies. As ENV105 continues through clinical trials for prostate and lung cancer, Kairos Pharma is committed to addressing the unmet medical needs affecting countless individuals.

Frequently Asked Questions

What are the main highlights of Kairos Pharma's 2024 achievements?

Kairos Pharma's major highlights include a successful IPO, partnerships to develop new biomarkers, and the commencement of key clinical trials for its lead drug, ENV105.

What is ENV105 and its relevance in cancer treatment?

ENV105 is an antibody therapy developed by Kairos Pharma that targets CD105 to combat drug resistance in various forms of cancer, including lung and prostate cancer.

What are the goals for Kairos Pharma in 2025?

In 2025, Kairos Pharma aims to advance its clinical trials, present at scientific meetings, and initiate crucial partnership discussions.

How does Kairos Pharma support cancer patients?

Kairos Pharma is dedicated to developing therapies that address significant medical needs and improve treatment outcomes for patients suffering from cancer.

Who is the CEO of Kairos Pharma Ltd.?

The CEO of Kairos Pharma Ltd. is John Yu, M.D., who oversees the company’s strategic direction and clinical development initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ALS Research Gains Momentum as ACT for ALS Law Signed

Updated Category News Views 36

A Major Stride in ALS Advocacy Today's not your usual day at the office for the folks championing the fight against ALS. With the President putting pen to paper, the ACT for ALS Act just turned into law, sending ripples through the community. Let me tell ya, legislation like this doesn't float by on a cloud—it's the result of grit, sleepless nights, and a dash of...

Continue Reading
SportsMed Expands to 58 Clinics, New Opening in Jersey City

Updated Category News Views 33

SportsMed Physical Therapy Expands with New Clinic Well, here we are, talking about expansion. And not just any expansion—I'm talking about SportsMed Physical Therapy flexing its muscles in Jersey City Heights, boosting their count to 58 clinics scattered across New Jersey and Connecticut. It's like watching a network of care roots spreading deeper into the region, and...

Continue Reading
Quarterhill's Q3 2026 Call Teases Insight into ITS Growth

Updated Category News Views 19

The clock's ticking down to November 10, and eyes are peeled for Quarterhill's Q3 financial debrief. Why the fuss? Well, they’ve made quite a name for themselves in the Intelligent Transportation System (ITS) scene, tossing AI into the mix to boot. If you’re playing in this space—or just sneaking a peek to see where tech’s steering us next—you might want to dial...

Continue Reading
Japan's RWE Market Transformation: TXP's Insightful Whitepaper

Updated Category News Views 10

Unraveling the Real-World Evidence Landscape in Japan The folks at TXP Medical just dropped a bombshell of a whitepaper that'll have Medical Affairs departments buzzing. Imagine waking up to a market that's exploding by over 500% in just a decade—yeah, I'm talking about the EMR-derived data market in Japan. These guys are saying it's gonna shoot from ¥3.9 billion in...

Continue Reading
PRIMA Invests £10M to Propel CC Forum's Global Reach

Updated Category News Views 98

Strategic Commitment for Global Impact You've got to hand it to these folks—they're on a mission to roll up their sleeves and tackle climate change head-on. Max Studennikoff, the brains behind CC Forum, just inked a Letter of Intent with Alexander Zhardanovsky, founder of PRIMA, punctuated by an eye-popping £10 million pledge. It's all about boosting the Forum’s...

Continue Reading
WhiteFiber: Expanding North Carolina Data Center Capacity

Updated Category News Views 20

WhiteFiber's Strategic Leap in North Carolina When a company starts throwing millions around, you better perk your ears up. WhiteFiber's $60 million plunge into North Carolina's dirt has filled their cart with two hefty data center projects. They're not messing around—just look at that cash down, with NASDAQ:WYFI betting big on these Yadkin County sites. Smart move or...

Continue Reading
Cambiotics Launches Key Trial on Reducing PFAS in Firefighters

Updated Category News Views 68

Pioneering Efforts to Combat 'Forever Chemicals' Cambiotics is stepping into some uncharted territory—tackling the tricky problem of PFAS accumulation in firefighters. If you’ve been following this, PFAS, or per- and polyfluoroalkyl substances, have been living rent-free in our bodies for years. Used in firefighting equipment and foams, these chemicals stick around,...

Continue Reading
FileInvite Transforms Complex Lending with Bold Platform Relaunch

Updated Category News Views 52

A New Era for Lending Documentation If you've been drumming your fingers waiting on loan paperwork to get sorted, FileInvite's latest move might just be the caffeine kick the lending world needs. Announced at the NAGGL Annual Conference, their souped-up platform has been redesigned as the beating heart of lending documentation. This isn't just a facelift folks—it's an...

Continue Reading
Tigo Energy Faces Class Action: Investor Implications

Updated Category News Views 46

Ah, here we go again, folks. Another day, another stock horror story. This time it’s Tigo Energy, Inc. (NASDAQ:TYGO) struggling under the microscope of a securities class action, care of the Law Offices of Howard G. Smith. If you’ve been keeping an eye on this one, buckle up—it's quite the mess. The Situation at Tigo Energy First off, let’s talk numbers. Tigo...

Continue Reading
Cerbo's AI Scribe Expands to Telehealth Success

Updated Category News Views 78

Cerbo Enhances Telehealth With AI Scribe Expansion The digital healthcare playground looks like it's getting a nudge toward efficiency with Cerbo's latest move. Just when you thought telehealth couldn't get much sharper, these folks have drawn a line in the sand with their AI Scribe, which now makes its presence felt in virtual visits. No more juggling a dozen screens...

Continue Reading

Top 5 Most Recently Viewed Articles

AbbVie Reports Encouraging Findings from TEMPO-2 Trial

Updated Category News Views 248

AbbVie Reports Positive Results from the Phase 3 TEMPO-2 Trial AbbVie (NYSE: ABBV) has made significant strides in the treatment of Parkinson's disease with its investigational drug, tavapadon. Recent findings from the pivotal Phase 3 TEMPO-2 trial have brought forth encouraging news for those affected by this challenging condition. Tavapadon demonstrated a notable...

Continue Reading
Understanding Recent Trends in Honda Motor Co's Stock Interest

Updated Category News Views 101

Trends in Short Interest for Honda Motor Co Honda Motor Co's short percent of float has recently dropped by 8.57%, according to the latest reporting. Currently, there are 4.27 million shares sold short, which accounts for 0.32% of all available shares. Considering the trading volume, it would typically require around 4.71 days for traders to cover their short positions on...

Continue Reading
HMH Distributes Historic Artwork to Northeast Museums

Updated Category News Views 88

A Treasure Chest of Art Finds New Homes When it comes to donating art, HMH isn't just about flipping a few pages of history; they're turning whole chapters. HMH, with a legacy stretching back centuries in the heartland of Boston, decided to part ways with 20 pieces of iconic art, spreading cultural seeds across some prominent northeastern museums. These aren't just any...

Continue Reading
Kasm Technologies Unveils Major Update to Workspaces Platform

Updated Category News Views 369

Exciting New Features in Kasm Workspaces v1.16 Kasm Technologies has introduced significant upgrades with the launch of Kasm Workspaces v1.16, enhancing its remote workplace streaming platform. This version integrates Kubernetes support, a Managed Egress feature, and an RDP Gateway, ensuring a more robust and secure user experience. Improved Remote Work Capabilities With...

Continue Reading
GoldQuest Mining Corp. Joins OTCQX: A Milestone Achievement

Updated Category News Views 138

GoldQuest Mining Corp. Upgrades to OTCQX This significant upgrade allows GoldQuest Mining Corp. (OTC: GDQMF) to access a broader spectrum of U.S. investors and enhance its market presence. By transitioning from the Pink Limited Market to the OTCQX Best Market, the company is aligned with higher financial standards and corporate governance practices. CEO’s Insight on...

Continue Reading